Printer Friendly

Aastrom Biosciences, Loyola University perform first ever transplants of ex vivo produced stem cells in cancer patients.

Aastrom Biosciences, Inc., Ann Arbor, MI, and Loyola University Medical Center, Maywood, IL, announced they have performed the first ever-successful transplants of ex vivo-produced human stem cells in breast cancer patients. Aastrom says the human stem cells for transplantation used in the Phase II clinical trial were produced using the AastromReplicell Cell Production System and SC-1 Therapy Kit.

The study included 19 patients with Stage II-IV (12 of whom had Stage II/IIIa) breast cancer who have undergone ablative chemotherapy to treat their cancer. Aastrom and Loyola said patients received transplants of stem cells produced from a small volume of autologous bone marrow in the AastromReplicell System using the SC-1 Therapy Kit. The study was intended to evaluate whether stem cells produced ex vivo could be used by themselves to restore blood and immune system function following aggressive chemotherapy and evaluated the time to engraftment of the patients' key infection fighting white blood cells and blood-clotting cells to control bleeding.

Aastrom has developed two therapy kits, the SC-1 Therapy Kit for the production of bone marrow-derived stem cells and the CB-1 Kit for the production of cord blood cells. The company has initiated a Phase III-pivotal clinical trial evaluating the SC-1 Therapy Kit in breast cancer patients and plans to initiate a Phase III-pivotal trial of the CB-1 Therapy Kit.

Contact: Todd Simpson - (734) 930-5777
COPYRIGHT 2000 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Aastrom Biosciences, Loyola University perform first ever transplants of ex vivo produced stem cells in cancer patients.
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Mar 27, 2000
Words:225
Previous Article:Paraplegic takes first steps in 10 years after implanted micro chip restores nerve function.
Next Article:ABIOMED forms collaborative agreement with Rabin Medical Center to test AbioCor implantable replacement heart.
Topics:


Related Articles
Aastrom awarded NIH grant for cord blood transplant program.
Aastrom enters distribution agreements with Gambro and Micromin to distribute AastromReplicell System.
Aastrom Biosciences initiates new product program for treatment of bone related diseases.
Aastrom Biosciences begins study of new stem cell transplant procedure in leukemia patients.
Aastrom Biosciences begins controlled clinical trial for cord blood therapy in leukemia patients.
Aastrom Biosciences patents cassette approach to growing human cells.
Karmanos Cancer Institute, Aastrom Biosciences create new center for cell therapy.
Aastrom receives patent covering integrated system for producing human cells.
Aastrom Biosciences receives orphan product designation from FDA for bone marrow stem cell product.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |